Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.35 |
| ▸ | MMP9 | P14780 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25412080 | 0.86 | KDM4E (0.43) | KDM4ERORCL3MBTL1IRAK4MMP2 | |
| SCHEMBL30597289 | 0.86 | KDM4E (0.43) | KDM4ERORCL3MBTL1IRAK4MMP2 | |
| SCHEMBL30597321 | 0.78 | NOS2 (0.44) | CCR2ALDH1A1 | |
| SCHEMBL26317567 | 0.78 | NOS2 (0.44) | CCR2ALDH1A1 | |
| SCHEMBL12596124 | 0.71 | AAK1 (0.41) | CCR2IGF1RGSK3BDYRK1A | |
| SCHEMBL12695294 | 0.71 | RAB9A (0.42) | CCR2RAB9AIGF1RGSK3BDYRK1A | |
| SCHEMBL12541193 | 0.71 | AAK1 (0.41) | CCR2IGF1RGSK3BDYRK1A | |
| SCHEMBL25412994 | 0.70 | KDM4E (0.48) | KDM4EL3MBTL1MMP2MMP9ALDH1A1 | |
| SCHEMBL2808080 | 0.70 | ATR (0.44) | CCR2IRAK4IGF1RGSK3BDYRK1A | |
| SCHEMBL15070169 | 0.70 | ATR (0.44) | IRAK4IGF1RGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | KDM4E 2304/4885RORC 3475/4885CCR2 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.